<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748926</url>
  </required_header>
  <id_info>
    <org_study_id>PKM17098</org_study_id>
    <secondary_id>U1111-1260-4526</secondary_id>
    <secondary_id>PRN1008-25</secondary_id>
    <nct_id>NCT04748926</nct_id>
  </id_info>
  <brief_title>Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants</brief_title>
  <official_title>A Randomized, Open-label, Phase I Study to Assess the Effects of Food and Formulation on the Pharmacokinetics of a Single Dose of Rilzabrutinib (SAR444671 [Formerly PRN1008]) in Healthy Male and Female Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Principia Biopharma, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To evaluate the impact of food on the pharmacokinetics (PK) of rilzabrutinib following&#xD;
           single oral doses to healthy subjects.&#xD;
&#xD;
        -  To evaluate the impact of formulation on the PK of rilzabrutinib following single oral&#xD;
           doses to healthy subjects&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      - To assess the safety and tolerability of single oral doses of rilzabrutinib administered&#xD;
      under fasted and fed conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration is approximately 43 days for each participant, including a screening&#xD;
      period of 2 to 28 days, treatment period of 12 days, and follow-up of 3 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Actual">May 21, 2021</completion_date>
  <primary_completion_date type="Actual">May 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: Cmax</measure>
    <time_frame>From Day 1 to Day 7</time_frame>
    <description>maximun plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: Tmax</measure>
    <time_frame>From Day 1 to Day 7</time_frame>
    <description>time to maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: AUC0-last</measure>
    <time_frame>From Day 1 to Day 7</time_frame>
    <description>area under the plasma concentration-time curve from zero to the last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: AUC0-inf</measure>
    <time_frame>From Day 1 to Day 7</time_frame>
    <description>area under the plasma concentration-time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: half-life</measure>
    <time_frame>From Day 1 to Day 7</time_frame>
    <description>terminal elimination phase half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: Cmax</measure>
    <time_frame>From Day 11 to Day 12</time_frame>
    <description>maximun plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: Tmax</measure>
    <time_frame>From Day 11 to Day 12</time_frame>
    <description>time to maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: AUC0-last</measure>
    <time_frame>From Day 11 to Day 12</time_frame>
    <description>area under the plasma concentration-time curve from zero to the last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: AUC0-inf</measure>
    <time_frame>From Day 11 to Day 12</time_frame>
    <description>area under the plasma concentration-time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: half-life</measure>
    <time_frame>From Day 11 to Day 12</time_frame>
    <description>terminal elimination phase half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent AE and treatment-emergent SAE</measure>
    <time_frame>Until Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive caplets after fast (treatment A) on Day 1 and caplets after meal (treatment B) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive caplets after meal (treatment B) on Day 1 and caplets after fast (treatment A) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rilzabrutinib SAR444671</intervention_name>
    <description>Pharmaceutical form: caplet Route of administration: oral</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rilzabrutinib SAR444671</intervention_name>
    <description>Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rilzabrutinib SAR444671</intervention_name>
    <description>Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        - Participants who are overtly healthy as determined by medical evaluation&#xD;
&#xD;
          -  Body mass index (BMI) within the range ≥18 and ≤31 kg/m2 (inclusive) and a minimum&#xD;
             body weight of 45 kg.&#xD;
&#xD;
          -  Female participant is eligible to participate if she is not pregnant or breastfeeding&#xD;
&#xD;
          -  Male participants are eligible to participate if they agree to refrain from donating&#xD;
             sperm and use contraception/barrier or be abstinent from intercourse&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  COVID-19 infection, positive test result for human immunodeficiency virus (HIV),&#xD;
             hepatitis B virus or hepatitis C virus antibody&#xD;
&#xD;
          -  Use of any prescription or over-the-counter (OTC) medication, herbal products, or&#xD;
             dietary supplements within 7 days&#xD;
&#xD;
          -  Participation in another clinical trial of a drug or device whereby the last&#xD;
             investigational drug/device administration is within 30 days or 5 half-lives,&#xD;
             whichever is longer, prior to the first dose of study drug.&#xD;
&#xD;
          -  Clinically significant abnormal in vital signs. - Any specific situation during study&#xD;
             implementation/course that may rise ethics considerations.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a subject's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

